- Home
- STOK vs RVNC Comparison
STOK vs RVNC Comparison
Compare STOK & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- RVNC
- Stock Information
- Founded
- STOK 2014
- RVNC 1999
- Country
- STOK United States
- RVNC United States
- Employees
- STOK N/A
- RVNC N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- STOK Health Care
- RVNC Health Care
- Exchange
- STOK Nasdaq
- RVNC Nasdaq
- Market Cap
- STOK 721.4M
- RVNC 599.6M
- IPO Year
- STOK 2019
- RVNC 2014
- Fundamental
- Price
- STOK $12.03
- RVNC $4.17
- Analyst Decision
- STOK Strong Buy
- RVNC Buy
- Analyst Count
- STOK 7
- RVNC 10
- Target Price
- STOK $21.40
- RVNC $10.23
- AVG Volume (30 Days)
- STOK 405.8K
- RVNC 2.8M
- Earning Date
- STOK 11-05-2024
- RVNC 11-07-2024
- Dividend Yield
- STOK N/A
- RVNC N/A
- EPS Growth
- STOK N/A
- RVNC N/A
- EPS
- STOK N/A
- RVNC N/A
- Revenue
- STOK $16,742,999.00
- RVNC $256,945,000.00
- Revenue This Year
- STOK $91.67
- RVNC $20.36
- Revenue Next Year
- STOK $5.45
- RVNC $31.66
- P/E Ratio
- STOK N/A
- RVNC N/A
- Revenue Growth
- STOK 81.08
- RVNC 25.82
- 52 Week Low
- STOK $3.77
- RVNC $2.30
- 52 Week High
- STOK $17.58
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- STOK 39.51
- RVNC 36.84
- Support Level
- STOK $13.39
- RVNC $3.36
- Resistance Level
- STOK $14.72
- RVNC $4.37
- Average True Range (ATR)
- STOK 0.68
- RVNC 0.31
- MACD
- STOK 0.03
- RVNC -0.15
- Stochastic Oscillator
- STOK 7.24
- RVNC 31.03
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.